Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of "Hold" by Analysts

Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) have earned a consensus rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $7.75.

Several equities research analysts have recently weighed in on the stock. Truist Financial dropped their target price on shares of Bausch Health Companies from $8.00 to $7.00 and set a "hold" rating for the company in a research report on Thursday, July 25th. Raymond James assumed coverage on Bausch Health Companies in a report on Wednesday, July 10th. They issued a "market perform" rating and a $8.00 price objective for the company. Evercore ISI raised Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th. Jefferies Financial Group lowered their price target on Bausch Health Companies from $13.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday, August 7th. Finally, Royal Bank of Canada upped their price target on Bausch Health Companies from $10.00 to $11.00 and gave the company a "sector perform" rating in a research report on Friday.

Insiders Place Their Bets

In other news, EVP Seana Carson sold 13,370 shares of Bausch Health Companies stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the sale, the executive vice president now directly owns 435,198 shares in the company, valued at $2,702,579.58. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.12% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in Bausch Health Companies during the second quarter valued at about $35,000. MQS Management LLC acquired a new position in shares of Bausch Health Companies in the second quarter valued at $71,000. Certuity LLC bought a new position in Bausch Health Companies in the second quarter worth $75,000. Bfsg LLC boosted its stake in Bausch Health Companies by 46.7% during the second quarter. Bfsg LLC now owns 11,450 shares of the company's stock worth $80,000 after buying an additional 3,643 shares in the last quarter. Finally, Kendall Capital Management bought a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $87,000. Institutional investors and hedge funds own 78.65% of the company's stock.

Bausch Health Companies Stock Up 6.3 %

Shares of NYSE BHC traded up $0.58 on Friday, hitting $9.78. The company had a trading volume of 3,457,099 shares, compared to its average volume of 2,943,669. The firm has a market capitalization of $3.59 billion, a P/E ratio of -20.38 and a beta of 0.77. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The business has a 50 day moving average of $7.55 and a two-hundred day moving average of $7.07.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts' consensus estimates of $1.03 by $0.09. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 850.93%. The business had revenue of $2.51 billion for the quarter, compared to analysts' expectations of $2.42 billion. During the same period in the previous year, the company posted $1.03 earnings per share. The business's revenue for the quarter was up 12.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Bausch Health Companies will post 3.6 earnings per share for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.